[1]孙宇婷 冯钰珉 戴科芳 郝进敏.Ddx5 和 Ddx17在人脑胶质瘤中的表达及其与病人生存期的关系[J].中国临床神经外科杂志,2020,(06):362-364.[doi:10.13798/j.issn.1009-153X.2020.06.008]
 SUN Yu-ting,FENG Yu-min,DAI ke-fang,et al.Relationship between expression levels of Ddx5 and Ddx17 in glioma tissues and survival time of patients with giloma[J].,2020,(06):362-364.[doi:10.13798/j.issn.1009-153X.2020.06.008]
点击复制

Ddx5 和 Ddx17在人脑胶质瘤中的表达及其与病人生存期的关系()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2020年06期
页码:
362-364
栏目:
论著
出版日期:
2020-06-15

文章信息/Info

Title:
Relationship between expression levels of Ddx5 and Ddx17 in glioma tissues and survival time of patients with giloma
文章编号:
1009-153X(2020)06-0362-03
作者:
孙宇婷 冯钰珉 戴科芳 郝进敏
054000 河北,邢台市第三医院神经外科(孙宇婷、冯钰珉、戴科芳、郝进敏)
Author(s):
SUN Yu-ting FENG Yu-min DAI ke-fang HAO Jin-min.
Department of Neurosurgery, Xingtai Third Hospital, Xingtai 054000, China
关键词:
胶质瘤预后Ddx5Ddx17
Keywords:
Ddx5 Ddx17 Glioma Prognosis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2020.06.008
文献标志码:
A
摘要:
目的 探讨Ddx5 和 Ddx17在人脑胶质瘤组织中的表达及其与病人生存期的关系。方法 收集2013年1月至2016年6月手术切除的胶质瘤组织120例和颅脑损伤内减压术中切取正常脑组织50例(对照组),采用免疫组化法检测Ddx5 和 Ddx17的表达水平,根据染色评分分为高表达和低表达。采用多因素Cox比例风险模型分析胶质瘤病人生存预后的影响因素。结果 胶质瘤组织Ddx5(70.00%,84/120)和Ddx17(65.83%,79/120)高表达率均明显高于正常脑组织[分别为28.00%(14/50)、38.00%(19/50);P<0.05]。多因素Cox比例风险模型分析结果显示Ddx5和Ddx17高表达是胶质瘤病人无进展生存期(PFS)和总生存期(OS)较短的独立影响因素(P<0.05)。与低表达组比较,Ddx5和Ddx17高表达组病人PFS和OS均明显缩短(P<0.05)。结论 人脑胶质瘤Ddx5和Ddx17呈高表达,二者均与胶质瘤病人的不良预后有关
Abstract:
Objective To investigate the relationship between the expression levels of Ddx5 and Ddx17 in glioma tissues and the survival time of patients with giloma. Methods The expression levels of Ddx5 and Ddx17 in glioma tissues obtained from 120 patients with gloma and in normal cerebral tissues obtained from 50 patients with traumatic brain injury were detected by immunohistochemistry. The glioma patients were divided into high expression group and low expression group. Cox proportional risk model was used to analyze the prognostic factors of glioma patients. Results The expression levels of DX5 and Dx17 in glioma tissues was significantly higher than those in the normal tissues (P<0.05). The progress-free survival (PFS) and overall survival (OS) of the high expression group were significantly shorter than those of the low expression group (P<0.05). The results of Cox analysis showed that high expression of Ddx5 and Ddx17 were the independent risk factors of PFS and OS in patients with glioma (P<0.05). Conclusion The expression levels of Ddx5 and Ddx17 in glioma tissues were significantly increased, which were related to the poor prognosis of glioma patients

参考文献/References:

[1] Gusyatiner O, Hegi ME. Glioma epigenetics: From subclas-sification to novel treatment options [J]. Semin Cancer Biol, 2018, 51: 50-58.
[2] Ma Z, Feng J, Guo Y, et al. Knockdown of DDX5 inhibits theproliferation and tumorigenesis in esophageal cancer [J]. Oncol Res, 2017, 25(6): 887-895.
[3] 葛瑞祥,盛莉莉,徐善水,等. 12-LOX 在神经胶质瘤中的表达及临床意义[J]. 中国肿瘤临床,2015,42(19):953-956.
[4] Luo Q, Que T, Luo H, et al. Upregulation of DEAD box he-licase 5 and 17 are correlated with the progression and poor prognosis in gliomas [J]. Pathol Res Pract, 2020, 216: 1-9.
[5] Quan Z, Zhang BB, Yin F, et al. DDX5 silencing suppresses the migration of basal cell carcinoma cells by down regula-ting JAK2/STAT3 pathway [J]. Technol Cancer Res Treat, 2019, 18: 1-12.
[6] 练晓文,游恒星,翟志浩,等. DDX5和HDGF在胶质瘤中的表达及其与预后的关系[J]. 中华神经医学杂志,2019,18(6):583-588.

相似文献/References:

[1]于 涛 黄正通 王振宇.椎管内脊膜囊肿的临床特征和治疗方法[J].中国临床神经外科杂志,2015,(11):654.[doi:10.13798/j.issn.1009-153X.2015.11.005]
 YU Tao,HUANG Zheng-tong,WANG Zhen-yu.Clinical features and treatment of intraspinal arachnoid cysts[J].,2015,(06):654.[doi:10.13798/j.issn.1009-153X.2015.11.005]
[2]常英男 王 策 赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
 CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(06):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[3]赛 克 陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[4]许 耿 路俊锋 杨 忠 施建斌 吴秋月 王 烨 庄冬晓 吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
 XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[5]云德波 杨宇焦 张 逵 范润金 张 渊 杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
 YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]谢宝树 张 林 王 宇 贾 锋 殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
 XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[7]黄书岚 成于思 王 辉 汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
 HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[8]林 雨 张 恺 李 帅 杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[9]周 量 刘 丛 张昌伟.早期栓塞术治疗动脉瘤性蛛网膜下腔出血的疗效[J].中国临床神经外科杂志,2016,(07):410.[doi:10.13798/j.issn.1009-153X.2016.07.007]
 ZHOU Liang,LIU Cong,ZHANG Chang-wei..Curative effect of early endovascular embolization on patients with ruptured intracranial aneurysms[J].,2016,(06):410.[doi:10.13798/j.issn.1009-153X.2016.07.007]
[10]陈吉钢 张丹枫 魏嘉良 邹 伟 侯立军.创伤性眶上裂综合征的治疗陈吉钢[J].中国临床神经外科杂志,2016,(04):200.[doi:10.13798/j.issn.1009-153X.2016.04.003]
 CHEN Ji-gang,ZHANG Dan-feng,WEI Jiang-liang,et al.Management of traumatic superior orbital fissure syndrome (report of 22 cases)[J].,2016,(06):200.[doi:10.13798/j.issn.1009-153X.2016.04.003]
[11]李剑峰 陈银生 赛 克 张湘衡 柯 超 杨群英 牟永告 许海雄 陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
 LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[12]任 勇,何 威,齐曼丽,等.TEM8在人脑胶质瘤中的表达及其意义[J].中国临床神经外科杂志,2016,(12):768.[doi:10.13798/j.issn.1009-153X.2016.12.012]
 REN Yong,HE Wei,QI Man-li,et al.Expression of TEM8 in human gliomas and its clinical meaning[J].,2016,(06):768.[doi:10.13798/j.issn.1009-153X.2016.12.012]
[13]孙连杰,麦麦提依明·托合提,杨小朋.与胶质瘤诊断及预后相关的分子标记物的研究进展[J].中国临床神经外科杂志,2018,(09):633.[doi:10.13798/j.issn.1009-153X.2018.09.022]
[14]穆寅东 赵天书 谢 清.脑胶质瘤SOX7基因的甲基化状态及临床意义[J].中国临床神经外科杂志,2019,(02):90.[doi:10.13798/j.issn.1009-153X.2019.02.009]
 MU Yin-dong,ZHAO Tian-shu,XIE Qing..Methylation state of SOX9 in human glioma and its clinical meanings[J].,2019,(06):90.[doi:10.13798/j.issn.1009-153X.2019.02.009]

备注/Memo

备注/Memo:
(2020-03-12收稿,2020-03-31修回)通讯作者:郝进敏,E-mail:zaisanzaisi123@163.com
更新日期/Last Update: 2020-06-15